PDCD1 and neoplasm: In the present study, tislelizumab, a humanized IgG4 anti-PD-1 monoclonal antibody, blocks the PD-1 receptor on T cells, thereby preventing its interaction with PD-L1 expressed on tumor cells and immune-suppressive cells.